EPRX
Income statement / Annual
Last year (2023), Eupraxia Pharmaceuticals Inc.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2023, Eupraxia Pharmaceuticals Inc.'s net income was -$37.39 M.
See Eupraxia Pharmaceuticals Inc.,s key income statements, including revenue, expenses, profit, and income.
Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
Operating Revenue |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
Cost of Revenue |
$209,911.00
|
$193,273.00
|
$111,529.00
|
$116,809.00
|
$201,936.00
|
$125,826.00
|
$85,376.00
|
Gross Profit |
-$209,911.00
|
-$193,273.00
|
-$111,529.00
|
-$116,809.00
|
-$201,936.00
|
-$125,826.00
|
-$85,376.00
|
Gross Profit Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
Research and Development Expenses |
$27.54 M
|
$17.20 M
|
$9.68 M
|
$859,781.00
|
$2.94 M
|
$6.64 M
|
$3.19 M
|
General & Administrative Expenses |
$9.65 M
|
$5.81 M
|
$8.89 M
|
$1.27 M
|
$3.01 M
|
$7.54 M
|
$1.70 M
|
Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
Selling, General & Administrative Expenses |
$9.65 M
|
$5.81 M
|
$8.89 M
|
$1.27 M
|
$3.01 M
|
$7.54 M
|
$1.70 M
|
Other Expenses |
$0.00
|
$0.00
|
-$2.26 M
|
$0.00
|
$1,737.00
|
$0.00
|
$0.00
|
Operating Expenses |
$37.92 M
|
$23.20 M
|
$18.68 M
|
$2.25 M
|
$6.16 M
|
$14.31 M
|
$4.97 M
|
Cost And Expenses |
$37.92 M
|
$23.20 M
|
$18.68 M
|
$2.25 M
|
$6.16 M
|
$14.31 M
|
$4.97 M
|
Interest Income |
$407,036.00
|
$569,319.00
|
$65,728.00
|
$427.00
|
$12,044.00
|
$1,106.00
|
$330.00
|
Interest Expense |
$1.58 M
|
$1.59 M
|
$1.30 M
|
$1.88 M
|
$1.46 M
|
$142,173.00
|
$52,806.00
|
Depreciation & Amortization |
$209,911.00
|
$193,273.00
|
$111,529.00
|
$116,809.00
|
$201,936.00
|
$125,826.00
|
$85,376.00
|
EBITDA |
-$36.75 M |
-$22.14 M |
-$21.96 M |
-$2.01 M |
-$5.94 M |
-$14.57 M |
-$4.89 M |
EBITDA Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
Operating Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
Total Other Income/Expenses Net |
-$2.29 M
|
-$64,066.00
|
-$5.46 M
|
-$1.76 M
|
-$1.08 M
|
-$2.95 M
|
-$143,131.00
|
Income Before Tax |
-$39.18 M
|
-$23.92 M
|
-$23.37 M
|
-$4.01 M
|
-$7.24 M
|
-$14.83 M
|
-$5.00 M
|
Income Before Tax Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
Income Tax Expense |
-$89,667.00
|
$930,519.00
|
-$1.34 M
|
$1.87 M
|
$1.40 M
|
-$1.46 M
|
-$627,563.00
|
Net Income |
-$37.39 M
|
-$23.26 M
|
-$22.99 M
|
-$4.00 M
|
-$7.18 M
|
-$13.23 M
|
-$4.32 M
|
Net Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
EPS |
-1.58 |
-1.21 |
-1.61 |
-0.31 |
-0.56 |
-1.03 |
-0.34 |
EPS Diluted |
-1.58 |
-1.21 |
-1.61 |
-0.31 |
-0.56 |
-1.03 |
-0.34 |
Weighted Average Shares Out |
$24.15 M
|
$19.29 M
|
$14.24 M
|
$12.87 M
|
$12.87 M
|
$12.87 M
|
$12.87 M
|
Weighted Average Shares Out Diluted |
$24.15 M
|
$19.29 M
|
$14.24 M
|
$12.87 M
|
$12.87 M
|
$12.87 M
|
$12.87 M
|
Link |
|
|
|
|
|
|
|